Brief: Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Rp-A601 Gene Therapy For Pkp2-Arrhythmogenic Cardiomyopathy
17/07/2025 12:57
Rocket Pharmaceuticals Inc RCKT.O: ROCKET PHARMACEUTICALS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR RP-A601 GENE THERAPY FOR PKP2-ARRHYTHMOGENIC CARDIOMYOPATHY Source text: ID:nBw5fsbZPa Further company coverage: RCKT.O
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08